Key points are not available for this paper at this time.
Our retrospective study aimed to determine how pulmonary arterial hypertension (PAH) influences the clinical outcomes of COVID-19 admissions by using data from the 2020 nationwide inpatient sample (NIS). Among the 1, 018, 915 adults who were hospitalized with COVID-19 in 2020, 155 also had a PAH diagnosis. After adjusting for all baseline demographics and co-morbidities through multivariate analysis, we found that in patients admitted with a principal diagnosis of COVID-19, PAH was not associated with an increased risk of mortality compared to those without PAH. (adjusted OR 0. 58 95% CI 0. 2-1. 6 p=0. 3). In addition, patients with both COVID-19 and PAH showed no statistically significant difference in the odds of requiring mechanical ventilation (adjusted OR 1. 1 95% CI 0. 5-2. 6 p=0. 9), vasopressor needs (adjusted OR 0. 4 95% CI 0. 1-3. 5 p=0. 4), acute kidney injury necessitating renal replacement therapy (adjusted OR 0. 7 95% CI 0. 3-1. 7 p=0. 5), mean length of stay (LOS) (11. 1 vs. 7. 5 days), adjusted difference 3. 1 95% CI -3. 8- 10. 1 p=0. 37) or mean total hospitalization charges (195, 815 vs 79, 082, adjusted difference 107, 146 95% CI -93, 939 - 308, 232 p=0. 29). Further studies are needed to investigate this subpopulation during the post-vaccination era to observe the effects of outcomes in these patients.
Tamimi et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: